As of June 7, 2025, Hubei Minkang Pharmaceutical Ltd (HBMK) reports a Gross Margin of 42.66%.
Gross Margin indicates the portion of sales revenue remaining after covering production costs, highlighting operational efficiency.
Historical Trend of Hubei Minkang Pharmaceutical Ltd's Gross Margin
Over recent years, Hubei Minkang Pharmaceutical Ltd's Gross Margin has shown a stable trend. The table below summarizes the historical values:
| Date | Gross Margin |
|---|---|
| 2013-12-31 | 42.66% |
| 2012-12-31 | 48.54% |
| 2011-12-31 | 47.83% |
This fluctuation highlights how Hubei Minkang Pharmaceutical Ltd manages its operational efficiency and pricing power over time.
Comparing Hubei Minkang Pharmaceutical Ltd's Gross Margin to Peers
To better understand Hubei Minkang Pharmaceutical Ltd's position, it's useful to compare its Gross Margin against industry peers. Below are selected comparisons:
| Company | Gross Margin |
|---|---|
| Hubei Minkang Pharmaceutical Ltd (HBMK) | 42.66% |
| Tree of Knowledge International Corp (TOKI.CN) | 2992.87% |
| Nutritional High International Inc (EAT.CN) | 2258.97% |
| MPX International Corp (MPXI.CN) | 65.40% |
| Targeted Medical Pharma Inc (TRGM) | 60.17% |
| Grown Rogue International Inc (GRIN.CN) | 51.76% |
Compared to its competitors, Hubei Minkang Pharmaceutical Ltd's Gross Margin is about average compared to peers, indicating industry-standard operational efficiency.